Vir Biotechnology names Aziz Sawaf as new CFO effective October 5, 2026
Theravance Biopharma's former CFO takes over Vir's finance, IT and investor relations functions as Brent Sabatini steps down from interim duties.
SEC filing
Latest
6 stories
Yesterday
Wednesday, September 23
Zymeworks closes acquisition of Theravance Biopharma
The Nasdaq-listed biotech finalized the merger on September 23, 2026, paying Theravance shareholders $17.00 in cash plus contingent value rights tied to ampreloxetine.
SEC filing
Zymeworks-Theravance merger CVR agreement details milestone and royalty terms
A contingent value rights agreement filed by Theravance Biopharma sets payment terms tied to licensing, sales, and a first commercial sale milestone for ampreloxetine, dated September 22, 2026.
SEC filing
Monday, September 14
COPD Foundation registers DELIVERY trial with Viatris, PARI, Theravance as collaborators
Monday, August 10
Theravance Biopharma reports Q2 2026 results, confirms Zymeworks deal on track for second half close
Theravance Biopharma said its previously announced acquisition by Zymeworks is expected to close in the second half of 2026, as YUPELRI revenue and cost cuts advanced.
SEC filing
Thursday, August 6
Zymeworks flags August 25 PDUFA date for zanidatamab, updates pipeline and Theravance timeline
Zymeworks said the FDA's target action date on zanidatamab in gastric cancer falls on August 25, 2026, while the Theravance Biopharma acquisition is still expected to close in the second half of the year.
SEC filing